Huahai Pharmaceutical: The subsidiary company HB0056 injection liquid has obtained clinical trial approval for new indications.

Huahai Pharmaceuticals announced that its subsidiaries Huao Tai and Huabo Biotechnology have received the approval and issuance of the "Drug Clinical Trial Approval Notice" for the HB0056 injection project with the newly added indication of "Idiopathic Pulmonary Fibrosis" from the National Medical Products Administration. As of now, the company has invested approximately 101 million yuan in the research and development of the HB0056 project. From 2024 to 2026, the drug has obtained approval for multiple clinical trials both domestically and internationally. However, there are various uncertainties in pharmaceutical product research and development, and the company will timely disclose any progress.